Klaus Wagner MD, PhD

Dr. Wagner has over 20 years of experience in cancer research and clinical drug development, most recently as Chief Medical Officer at Boundless Bio, Inc., where he guided the clinical development of the company’s pipeline of novel small molecule therapeutics targeting patients with oncogene amplifications. Prior to that, Dr. Wagner built and led an integrated clinical development organization at Inhibrx, Inc., where he was responsible for advancing four single-domain antibody-based and Fc fusion protein therapeutic candidates from pre-IND into the clinic, including three oncology programs. Dr. Wagner trained and completed his fellowship in Medical Oncology at MD Anderson Cancer Center. As a board-certified Medical Oncologist, who continues to treat cancer patients, he practiced at Banner MD Anderson Cancer Center and served as Adjunct Assistant Professor in the Department of Thoracic, Head & Neck Medical Oncology at MD Anderson Cancer Center, where he led molecularly targeted therapy and cancer immunotherapy trials in non-small cell lung cancer as a local principal investigator. His scientific work at Genentech, Inc. and the Genomics Institute of the Novartis Research Foundation focused on molecularly targeted cancer drug discovery and predictive biomarker development. Dr. Wagner received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany and was a scholar of the German National Academic Scholarship Foundation.